Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Niagen Bioscience (NASDAQ:NAGE) from a "hold" to a buy rating in a report issued Saturday.
• Analyst coverage totals three Buys and one Hold, yielding a consensus "Moderate Buy" and a consensus price target of $16.00; Canaccord cut its target to $13 while keeping a Buy, and Weiss Ratings maintained a Hold (c).
• Shares opened at $4.20 with a market cap of $336.3M, a 52‑week range of $4.20–$14.69 and a P/E of 21, and institutional investors own about 15.4% after modest stake increases by firms like Swiss National Bank, Price T. Rowe and Wells Fargo.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

A number of other research firms have also recently commented on NAGE. Weiss Ratings restated a "hold (c)" rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Niagen Bioscience Stock Performance

Niagen Bioscience stock opened at $4.20 on Friday. The stock has a market capitalization of $336.34 million, a price-to-earnings ratio of 21.00 and a beta of 2.11. Niagen Bioscience has a 52-week low of $4.20 and a 52-week high of $14.69. The stock's 50 day moving average price is $5.22 and its two-hundred day moving average price is $6.61.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its position in Niagen Bioscience by 5.7% in the 4th quarter. SG Americas Securities LLC now owns 54,649 shares of the company's stock valued at $348,000 after purchasing an additional 2,950 shares during the period. Swiss National Bank increased its stake in Niagen Bioscience by 3.0% during the 4th quarter. Swiss National Bank now owns 110,100 shares of the company's stock valued at $700,000 after purchasing an additional 3,200 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Niagen Bioscience by 5.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,342 shares of the company's stock worth $384,000 after buying an additional 3,215 shares during the last quarter. Financial Consulate Inc. acquired a new position in Niagen Bioscience during the third quarter worth $33,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Niagen Bioscience by 6.9% in the fourth quarter. Wells Fargo & Company MN now owns 58,337 shares of the company's stock valued at $371,000 after buying an additional 3,740 shares in the last quarter. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.